A case for conducting business-to-business experiments with multi-arm multi-stage adaptive designs

被引:1
|
作者
Legare, Jonathan [1 ]
Yao, Ping [1 ]
Lo, Victor S. Y. [1 ]
机构
[1] Fidel Investments, 245 Summer St, Boston, MA 02210 USA
关键词
Randomized controlled trial; Multi-arm multi-stage; Adaptive design; Simulation study; Experimental design; Business-to-business; CLINICAL-TRIALS;
D O I
10.1057/s41270-022-00177-4
中图分类号
F [经济];
学科分类号
02 ;
摘要
Many businesses conduct experiments to scientifically test, measure, and optimize decisions in areas like sales, marketing, and operations efficiency. While randomized controlled trials (RCTs) or A/B tests are the dominant method for conducting business experiments especially for business-to-consumer marketing, adaptive designs have yet to make extensive inroads outside of the pharmaceutical and medical industries. In this study, we aim to raise awareness of the applicability and advantages of multi-arm multi-stage adaptive designs outside of clinical settings and we use simulations to demonstrate the value of these designs to modern business experiments, with a focus on business-to-business experiments such as testing alternative sales techniques. Our simulation results show that, compared to RCT, multi-arm multi-stage adaptive designs (MAMS) can reduce the sample size requirements and expected time to experiment completion whilst maintaining a similar level of statistical power. We also demonstrate that these benefits can translate into actual cost savings in conjunction with shorter time to market, resulting in higher overall efficiency over the traditional RCTs. MAMS serves as a strong alternative methodology in experiments where not all customers can be contacted at once such as business-to-business campaigns and general live channel programs which typically take weeks to months to complete.
引用
收藏
页码:490 / 502
页数:13
相关论文
共 50 条
  • [1] A case for conducting business-to-business experiments with multi-arm multi-stage adaptive designs
    Jonathan Legare
    Ping Yao
    Victor S. Y. Lo
    Journal of Marketing Analytics, 2023, 11 : 490 - 502
  • [2] A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials
    Wason, James M. S.
    Trippa, Lorenzo
    STATISTICS IN MEDICINE, 2014, 33 (13) : 2206 - 2221
  • [3] A comparison of bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials
    James Wason
    Lorenzo Trippa
    Trials, 14 (Suppl 1)
  • [4] Bayesian adaptive decision-theoretic designs for multi-arm multi-stage clinical trials
    Bassi, Andrea
    Berkhof, Johannes
    de Jong, Daphne
    van de Ven, Peter M.
    STATISTICAL METHODS IN MEDICAL RESEARCH, 2021, 30 (03) : 717 - 730
  • [5] Some practical considerations in the design of multi-arm multi-stage designs
    Wulff, Jerome
    Demiris, Nikolaos
    TRIALS, 2019, 20
  • [6] Multi-arm multi-stage designs with fixed stage-wise sample sizes
    Grayling, Michael
    Wason, James
    TRIALS, 2019, 20
  • [7] MULTI-ARM MULTI-STAGE RANDOMISED TRIALS
    Parmar, Mahesh
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S91 - S91
  • [8] NOVEL CLINICAL TRIAL DESIGNS IN PAEDIATRIC CANCER: MULTI-ARM MULTI-STAGE (MAMS) DESIGNS
    Wheatley, K.
    Moroz, V.
    Houlton, A.
    Kearns, P.
    PEDIATRIC BLOOD & CANCER, 2015, 62 : S227 - S227
  • [9] Factorial versus multi-arm multi-stage designs for clinical trials with multiple treatments
    Jaki, Thomas
    Vasileiou, Despina
    STATISTICS IN MEDICINE, 2017, 36 (04) : 563 - 580
  • [10] Treatment selection in multi-arm multi-stage designs: With application to a postpartum haemorrhage trial
    Choodari-Oskooei, Babak
    Thwin, Soe Soe
    Blenkinsop, Alexandra
    Widmer, Mariana
    Althabe, Fernando
    Parmar, Mahesh K. B.
    CLINICAL TRIALS, 2023, 20 (01) : 71 - 80